NeuroMetrix Inc (NURO)
4.426
+0.03
(+0.60%)
USD |
NASDAQ |
May 08, 16:00
4.40
-0.03
(-0.60%)
After-Hours: 20:00
NeuroMetrix Research and Development Expense (Quarterly): 0.7324M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.7324M |
| September 30, 2023 | 0.5927M |
| June 30, 2023 | 0.7535M |
| March 31, 2023 | 0.6994M |
| December 31, 2022 | 0.5384M |
| September 30, 2022 | 1.075M |
| June 30, 2022 | 0.9158M |
| March 31, 2022 | 0.7106M |
| December 31, 2021 | 0.9971M |
| September 30, 2021 | 0.7246M |
| June 30, 2021 | 0.6415M |
| March 31, 2021 | 0.2333M |
| December 31, 2020 | 0.5447M |
| September 30, 2020 | 0.6527M |
| June 30, 2020 | 0.6603M |
| March 31, 2020 | 0.5336M |
| December 31, 2019 | 0.7368M |
| September 30, 2019 | 0.4751M |
| June 30, 2019 | 1.035M |
| March 31, 2019 | 0.8551M |
| December 31, 2018 | 1.060M |
| September 30, 2018 | 1.178M |
| June 30, 2018 | 1.617M |
| March 31, 2018 | 1.280M |
| December 31, 2017 | 0.8762M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.8406M |
| June 30, 2017 | 0.8776M |
| March 31, 2017 | 0.9033M |
| December 31, 2016 | 0.9071M |
| September 30, 2016 | 1.203M |
| June 30, 2016 | 1.128M |
| March 31, 2016 | 1.157M |
| December 31, 2015 | 1.069M |
| September 30, 2015 | 0.9408M |
| June 30, 2015 | 0.9823M |
| March 31, 2015 | 0.9025M |
| December 31, 2014 | 0.8021M |
| September 30, 2014 | 0.9453M |
| June 30, 2014 | 1.465M |
| March 31, 2014 | 0.8637M |
| December 31, 2013 | 0.7106M |
| September 30, 2013 | 0.7403M |
| June 30, 2013 | 0.9138M |
| March 31, 2013 | 1.073M |
| December 31, 2012 | 0.5666M |
| September 30, 2012 | 0.9804M |
| June 30, 2012 | 1.021M |
| March 31, 2012 | 0.9781M |
| December 31, 2011 | 0.8276M |
| September 30, 2011 | 0.8296M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.2333M
Minimum
Mar 2021
1.075M
Maximum
Sep 2022
0.6975M
Average
0.6994M
Median
Mar 2023
Research and Development Expense (Quarterly) Benchmarks
| Teleflex Inc | 37.30M |
| Perspective Therapeutics Inc | 6.08M |
| Xtant Medical Holdings Inc | 0.492M |
| Asensus Surgical Inc | 8.614M |
| Catheter Precision Inc | -0.011M |